Charles River Laboratories International, Inc. (NYSE:CRL)’s share price hit a new 52-week high during mid-day trading on Thursday . The stock traded as high as $109.75 and last traded at $109.66, with a volume of 137,323 shares traded. The stock had previously closed at $109.58.

Several brokerages recently issued reports on CRL. Royal Bank Of Canada began coverage on Charles River Laboratories International in a research note on Tuesday, September 19th. They set a “sector perform” rating and a $110.00 price objective on the stock. Jefferies Group LLC restated a “buy” rating and set a $120.00 price objective on shares of Charles River Laboratories International in a research note on Tuesday, September 12th. Robert W. Baird restated a “buy” rating and set a $114.00 price objective on shares of Charles River Laboratories International in a research note on Friday, September 1st. BidaskClub upgraded Charles River Laboratories International from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, August 22nd. Finally, Zacks Investment Research cut Charles River Laboratories International from a “buy” rating to a “hold” rating in a research note on Friday, August 11th. Six research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $99.59.

The company has a market cap of $5.23 billion, a P/E ratio of 28.97 and a beta of 0.96. The stock’s 50 day moving average price is $106.15 and its 200-day moving average price is $97.03.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings results on Wednesday, August 9th. The medical research company reported $1.29 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.22 by $0.07. The business had revenue of $469.13 million for the quarter, compared to analyst estimates of $458.25 million. Charles River Laboratories International had a return on equity of 27.02% and a net margin of 10.13%. Charles River Laboratories International’s quarterly revenue was up 8.1% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.20 EPS. On average, equities analysts anticipate that Charles River Laboratories International, Inc. will post $5.10 EPS for the current fiscal year.

In related news, Chairman James C. Foster sold 9,516 shares of the business’s stock in a transaction on Monday, July 10th. The stock was sold at an average price of $98.92, for a total value of $941,322.72. Following the sale, the chairman now owns 361,171 shares of the company’s stock, valued at approximately $35,727,035.32. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider David Ross Smith sold 2,552 shares of the business’s stock in a transaction on Monday, August 14th. The shares were sold at an average price of $67.10, for a total value of $171,239.20. Following the completion of the sale, the insider now directly owns 11,671 shares in the company, valued at approximately $783,124.10. The disclosure for this sale can be found here. In the last ninety days, insiders sold 25,880 shares of company stock worth $2,541,668. 2.20% of the stock is owned by insiders.

Institutional investors have recently bought and sold shares of the business. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Charles River Laboratories International by 12.7% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,791 shares of the medical research company’s stock worth $181,000 after purchasing an additional 202 shares in the last quarter. Riverhead Capital Management LLC boosted its stake in Charles River Laboratories International by 14.7% in the second quarter. Riverhead Capital Management LLC now owns 1,931 shares of the medical research company’s stock worth $195,000 after purchasing an additional 247 shares in the last quarter. Cambridge Advisors Inc. acquired a new position in Charles River Laboratories International in the second quarter worth $202,000. Advisor Partners LLC acquired a new position in Charles River Laboratories International in the second quarter worth $208,000. Finally, Campbell & CO Investment Adviser LLC acquired a new position in Charles River Laboratories International in the second quarter worth $217,000. 95.37% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: This piece was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece on another publication, it was copied illegally and republished in violation of U.S. and international copyright & trademark law. The legal version of this piece can be viewed at https://www.thecerbatgem.com/2017/10/05/charles-river-laboratories-international-inc-crl-sets-new-52-week-high-at-109-75.html.

About Charles River Laboratories International

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Receive News & Stock Ratings for Charles River Laboratories International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International Inc. and related stocks with our FREE daily email newsletter.